GRINDEKS More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 44 | - |
| Director of Finance/CFO | 64 | 02-12-31 | |
Dmitry Saikovky
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kirovs Lipmans
CHM | Chairman | 83 | 02-12-31 |
Anna Lipmane
BRD | Director/Board Member | 76 | 07-12-31 |
Filips Lipmans
BRD | Director/Board Member | 46 | - |
Grindeks is the Baltic leader pharmaceutical group. Net sales break down by activity as follows:
- research, development and manufacturing of pharmaceuticals (94.9%): medicines for the treatment of cardiovascular diseases, cancers and central nervous system disorders, analgesic products, treatments of cough and flu, etc.;
- production of pharmaceutical active ingredients (5.1%).
Net sales break down geographically as follows: Latvia (6.6%), Russia (59.6%), Lithuania (4%), Estonia (1.7%) and other (28.1%).
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +22.41% | 44.1B | |
| +17.11% | 21.97B | |
| +10.40% | 13.27B | |
| +6.65% | 13.22B | |
| +37.45% | 11.36B | |
| -8.53% | 7.07B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.09% | 5.23B |
